Navigation Links
Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
Date:6/14/2010

0 patients from sites throughout Europe, South America, Asia Pacific and the Middle East.

About Non-Small Cell Lung Cancer (NSCLC)(1)

Non-small cell lung cancer accounts for 85-90% of diagnosed lung cancers and is a disease in which malignant (cancer) cells form in the tissues of the lung. It is characterized by several types of lung cancers, each of which grow and spread in different ways, including: squamous cell carcinoma, adenocarcinoma, and large cell carcinoma.

Every year 1.4 million people worldwide will be diagnosed with lung cancer.  There are nearly 205,000 new cases in the United States and approximately 375,000 new cases in Europe each year.  Annual deaths as a result of non small cell lung cancer are estimated at 160,000 in the United States and 342,000 in Europe.

Nexavar's Differentiated Mechanism
Nexavar, an oral anti-cancer therapy, is currently approved in more than 90 countries for liver cancer and in more than 95 countries for the treatment of patients with advanced kidney cancer.  Nexavar inhibits both the tumor cell and tumor vasculature.  In preclinical studies, Nexavar has been shown to inhibit members of two classes of kinases thought to be involved in both cell proliferation (growth) and angiogenesis (blood supply) – two important processes that enable cancer growth.  These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFRB, KIT, FLT-3 and RET.

Nexavar is also being evaluated by the companies, international study groups, government agencies and individual investigat
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Poniard Announces Final Data from Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
2. Onyx Pharmaceuticals Presents Interim Results of Phase 1b Carfilzomib Combination Trial
3. Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
4. NeuroDerm Successfully Completes Enrollment and Dosing in a Phase 1 Clinical Study of ND0611 Dermal Patch for Parkinsons Disease
5. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
6. Bayer HealthCare Pharmaceuticals, Inc. Announces Results of a Phase 3 Clinical Trial of Gadobutrol
7. Mpex Pharmaceuticals Presents Positive Phase 2 Clinical Trial Results of Aeroquin(TM) (MP-376) Treatment in Cystic Fibrosis Patients
8. CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate
9. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
10. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
11. SARcode Corporation Announces Phase 2 Study Results of SAR 1118 Topical Ophthalmic Solution for the Treatment of Dry Eye
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... N.J. , Sept. 1, 2015 Konica ... CS-7s Computed Radiography (CR) system, designed to deliver enterprise ... By utilizing the same Control Station as the Konica ... assured with an upgrade path from CR to DR. ... imaging to help improve workflow with unparalleled reliability and ...
(Date:9/1/2015)... UT Southwestern Medical Center President Dr. ... U.S. Representatives Michael C. Burgess , M.D., and ... the 21 st Century Cures Act, bipartisan legislation ... the United States Senate. ... Sciences members, department chairs, center directors, and leading researchers ...
(Date:9/1/2015)... 2015   Alpha Imaging LLC , a leading distributor of ... announced today that they have been awarded exclusive rights to represent ... Michigan.   The new territory supplements Alpha Imaging,s existing Shimadzu sales and ... Ohio , Indiana , Pennsylvania ... , West Virginia , Delaware ...
Breaking Medicine Technology:Konica Minolta Launches New CR System with Low-Cost Upgrade Path to DR 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 4U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 5Alpha Imaging Expands Shimadzu Territory 2
... BEIJING, May 7, 2012 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. ... leading plasma-based biopharmaceutical companies in the People,s Republic of China, ... covering its first quarter 2012 results on May 9, 2012 ... p.m. in China on the same day. Hosting ...
... S. Weinstock and G. Scott Vezina of ... obtained a $78.5 million verdict on behalf of a child ... negligence. The child, now 3 years old, has severe spastic ... of an emergency cesarean section delivery. The case was tried, ...
Cached Medicine Technology:China Biologic Products to Host Earnings Conference Call on May 9, 2012 at 8:00 a.m. EDT (NY) 2$78.5 Million Jury Verdict In Philadelphia Birth Injury Case 2$78.5 Million Jury Verdict In Philadelphia Birth Injury Case 3
(Date:9/1/2015)... ... September 01, 2015 , ... Agriculture innovation, urban farming, local food access, ... to be discussed at Seedstock’s 4th Annual Sustainable Agriculture Conference : “Innovation and ... , In addition to keynotes Pierre Sleiman, founder and CEO of Go Green ...
(Date:9/1/2015)... ... 01, 2015 , ... METTLER TOLEDO has announced an upcoming ... requirements“ , featuring Ed Szczesny (Quality Assurance, Rhodes Pharmaceuticals) as guest presenter. This ... , Calibration, qualification, and the appropriate level of routine testing for laboratory ...
(Date:9/1/2015)... NY (PRWEB) , ... September 01, 2015 , ... ... as the 2015-2016 Distinguished Nurse Scholar-in Residence at the Institute of Medicine (IOM) ... Professor of Biomedical Informatics at Columbia University School of Nursing. A member of ...
(Date:9/1/2015)... ... September 01, 2015 , ... CanAm Enterprises LLC, (“CanAm”) is ... green cards (I-829 petition approval) from the USCIS through an investment in one ... of the EB-5 visa process for immigrant investors to become lawful permanent residents ...
(Date:9/1/2015)... MO (PRWEB) , ... September 01, 2015 , ... ... Wednesday, September 9, 2015 from 5:00 to 8:00 pm at the Marriott Indianapolis ... and groups with career opportunities will be attending from across the country. All ...
Breaking Medicine News(10 mins):Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 2Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 3Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 4Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 5Health News:Live Webinar from Pharmaceutical Technology and METTLER TOLEDO on Calibration and Qualification of Laboratory Instruments 2Health News:Columbia Nursing’s Suzanne Bakken Named Distinguished Institute of Medicine Nurse Scholar-in-Residence 2Health News:CanAm Enterprises Reaches Another Milestone with More Than 1,500 I-829 Petition Approvals 2Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 2Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 3Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 4
... DENVER The six-minute walking distance test (6MWD), a ... and physical activity, is an effective tool for understanding ... (COPD), according to a three-year global study of patients ... The study will be presented at the ATS 2011 ...
... advanced prostate cancer suggest they can be good candidates ... found a 20-year survival rate for 80 percent of ... the prostate, known as cT3 prostate cancer, and treated ... gland. Previously, patients found to have cT3 prostate cancer ...
... the ability of lung cells to divide may play a ... of chronic obstructive pulmonary disease (COPD), according to a study ... presented at the ATS 2011 International Conference in Denver. ... had an impaired ability to divide, or had lost their ...
... technique using cells from the interior of the nose could ... most treatable stages, according to a study conducted by ... the ATS 2011 International Conference. "Our data suggests that ... interior surface of the nose may serve as a non-invasive ...
... Baltimore have identified new compounds whichrelax airway muscles and may ... and asthma. The bitter-tasting compounds are at least as, if ... these diseases, and may present new options for treatment. ... 2011 International Conference in Denver. "We have identified compounds ...
... (HealthDay News) -- As Americans head toward attics, roofs and ... warn that spring cleaning can lead to a spring visit ... people injured themselves on a stepladder, and more than 41,000 ... the U.S. Consumer Product Safety Commission. In addition, over 127,000 ...
Cached Medicine News:Health News:'Walking distance' test an accurate indicator of disease severity in patients with COPD 2Health News:Cell division abnormality contributes to inflammation in COPD 2Health News:Gene expression changes in nasal cells may help identify lung cancer in earliest stages 2Health News:Gene expression changes in nasal cells may help identify lung cancer in earliest stages 3Health News:Researchers move closer to identifying new class of asthma, COPD drugs 2Health News:Researchers move closer to identifying new class of asthma, COPD drugs 3Health News:Spring Cleaning Lands Many Americans in Hot Water 2
Enzyme immunoassay for the quantitative determination of IgG autoantibodies against type IV collagen of glomerular or alveolar basement membrane (GBM) in serum and plasma....
... immunosorbent assay method for the semi-quantitative ... GBM in human serum. The results ... as an aid in the diagnosis ... of anti-GBM antibodies including Goodpastures Syndrome. ...
... intimately involved in the control of the ... tissues, which synthesize and secrete male and ... circulating FSH is controlled by these sex ... FSH Quantitative Test Kit is based ...
... Class II Direct to High Res SSP kits provide ... single tray. Locus specific typing on a single tray ... Straight from genomic DNA to high resolution results, ... level typing with a single tray , Unique reaction ...
Medicine Products: